133 completed, 42 terminated, 13 withdrawn, 6 active not recruiting. 97 Phase 2, 81 Phase 1, 29 Not applicable, 9 Phase 3, 7 Early Phase 1.
Follow Stage IV Breast Cancer: new trials by email Literature Review of Stage IV Breast Cancer trials Research Report on Stage IV Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases Primary Tumor Resection, Standard systemic therapy - Breast Cancer, Stage IV Breast Cancer | Not applicable | Not yet recruiting | West China Hospital | 216 | 2026-09-01 | 2026-07-07 |
| A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer Abemaciclib, Radiation Therapy - Metastatic Breast Cancer, Stage IV Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 28 | 2024-11-15 | 2026-05-28 |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer Nab-Paclitaxel, Paclitaxel, Docetaxel - Breast Cancer Female, Breast Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 72 | 2024-08-08 | 2026-08-06 |
| Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer Discontinuation of Anti-HER-2 Maintenance Treatment - HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer | Not applicable | Active not recruiting | University of Miami | 20 | 2023-07-17 | 2026-09-24 |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel - Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer | Phase 3 | Active not recruiting | Gilead Sciences | 654 | 2023-05-08 | 2025-10-03 |
| Ask Questions (ASQ):Implementation of a Communication Intervention Behavioral Intervention - Stage II Breast Cancer, Stage III Breast Cancer | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 81 | 2021-08-25 | 2023-08-16 |
| Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer LTLD, MR-HIFU induced hyperthermia, Cyclophosphamide - Metastatic Breast Cancer, Breast Cancer | Phase 1 | Unknown | UMC Utrecht | 12 | 2021-03-01 | 2021-02-17 |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer Educational Video and QPL List, Usual Care - Stage IV Melanoma, Advanced Lung Cancer | Not applicable | Completed | Massachusetts General Hospital | 199 | 2021-01-23 | 2026-08-25 |
| Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients Stereotactic Body Radiation Therapy (SBRT) - Stage IV Breast Cancer | Not applicable | Unknown | Campus Bio-Medico University | 30 | 2020-07-10 | 2022-02-08 |
| Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients surgery combined with systemic therapy, systemic therapy - Stage IV Breast Cancer | Phase 2 | Withdrawn | Henan Cancer Hospital | 2020-04-15 | 2024-03-04 | |
| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites Canady Helios Cold Plasma Scalpel - Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer | Not applicable | Unknown | Jerome Canady, M.D. | 20 | 2019-07-30 | 2021-08-09 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide Karanahan - Stage IV Breast Cancer | Early Phase 1 | Unknown | KARANAHAN | 20 | 2018-11-01 | 2024-04-11 |
| Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer Dibenzyl trisulphide capsules, Stage IV Breast Cancer Placebo, Stage IV: Colon Cancer Placebo - Stage IV Prostate Cancer, Stage IV Colon Cancer | Early Phase 1 | Unknown | The University of The West Indies | 104 | 2018-10-01 | 2019-10-08 |
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Atezolizumab, Cobimetinib, Idasanutlin - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2018-07-10 | 2021-08-11 |
| G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer G1T48, Palbociclib - Carcinoma, Ductal, Breast, Breast Cancer Female | Phase 1 | Completed | G1 Therapeutics, Inc. | 107 | 2018-05-09 | 2026-09-21 |
| Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer Laboratory Biomarker Analysis, Meditation-Based Stress Reduction Program, Quality-of-Life Assessment - Stage IV Breast Cancer | Not applicable | Completed | Roswell Park Cancer Institute | 44 | 2017-12-13 | 2024-08-30 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration - Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm | Not applicable | Completed | Rutgers, The State University of New Jersey | 14 | 2017-12-06 | 2021-04-08 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine - HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Completed | George W. Sledge Jr. | 18 | 2017-10-30 | 2022-10-19 |
Showing 20 of 203. Sign in to see all of them.
Breast Neoplasms (203) · Breast Neoplasms, Male (63) · Triple Negative Breast Neoplasms (26) · Carcinoma, Ovarian Epithelial (19) · Carcinoma, Non-Small-Cell Lung (18) · Colonic Neoplasms (16) · Carcinoma, Renal Cell (15) · Pancreatic Neoplasms (14) · Rectal Neoplasms (13) · Prostatic Neoplasms (12) · Stomach Neoplasms (11) · Melanoma (10) · Ovarian Neoplasms (10) · Urinary Bladder Neoplasms (10) · Uterine Cervical Neoplasms (10)
Breast Diseases (203) · Neoplasms by Site (203) · Skin Diseases (203) · Skin and Connective Tissue Diseases (203) · Neoplasms (201) · Neoplasms by Histologic Type (44) · Urogenital Diseases (40) · Urogenital Neoplasms (40) · Neoplasms, Glandular and Epithelial (39) · Carcinoma (38) · Female Urogenital Diseases (37) · Female Urogenital Diseases and Pregnancy Complications (37) · Endocrine Gland Neoplasms (35) · Endocrine System Diseases (35) · Genital Diseases (34)
Trastuzumab (25) · Paclitaxel (21) · Taxes (19) · Cyclophosphamide (12) · Carboplatin (11) · Albumin-Bound Paclitaxel (10) · Capecitabine (9) · 130-nm albumin-bound paclitaxel (8) · Lapatinib (8) · Anastrozole (7) · Letrozole (7) · Tamoxifen (7) · Vorinostat (7) · Bevacizumab (6) · Doxorubicin (6)
National Cancer Institute (NCI) (63) · University of Washington (21) · Northwestern University (9) · City of Hope Medical Center (8) · Mayo Clinic (6) · University of Southern California (6) · Vanderbilt-Ingram Cancer Center (6) · Wake Forest University Health Sciences (6) · Meabco A/S (5) · Burzynski Research Institute (3) · Emory University (3) · Fred Hutchinson Cancer Center (3) · Jonsson Comprehensive Cancer Center (3) · University of Chicago (3) · Dana-Farber Cancer Institute (2)
United States (181) · Canada (9) · Thailand (5) · Israel (3) · Italy (3) · Russia (3) · South Korea (3) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2) · China (2) · France (2) · Germany (2) · Greece (2)
Lupe Salazar (6) · Mary Disis (5) · Hannah Linden (4) · Charles Shapiro (3) · Harold Burstein (3) · Massimo Cristofanilli (3) · Stanislaw R. Burzynski, MD, PhD (3) · Edith Perez (2) · Elaina Gartner (2) · Funda Meric-Bernstam (2) · Jennifer Specht (2) · Joanne Mortimer (2) · Joseph Sparano (2) · Patricia LoRusso (2) · Rita Nanda (2)
PMID 25473312, PMID 18650156, PMID 18974373, PMID 19153124, PMID 19720923, PMID 20357034, PMID 22200869, PMID 22418699, PMID 24170452, PMID 25260365, PMID 25792808, PMID 25965900, PMID 26059540, PMID 26062933, PMID 26123926, PMID 26170717, PMID 26611425, PMID 27190628, PMID 28114604, PMID 28764748, PMID 28817727, PMID 30542377, PMID 30666153, PMID 30846327, PMID 30850872, PMID 31194225, PMID 31194228, PMID 31277699, PMID 31703728, PMID 31849532, PMID 32060053, PMID 32193378, PMID 32375690, PMID 32641862, PMID 32692450, PMID 33243800, PMID 33885704, PMID 34749008, PMID 34995128, PMID 35365139, PMID 35429391, PMID 35771552, PMID 36228177, PMID 36279134, PMID 36326756, PMID 36892847, PMID 37007063, PMID 37294342, PMID 37499870, PMID 37509349
P30CA015704 (10), P30CA060553 (7), U01CA062490 (7), P30CA015083 (6), U10CA021115 (6), N01CM17003 (5), N01CM62204 (4), P30CA016672 (4), U01CA062487 (4), N01CM62209 (3), P30CA012197 (3), P30CA013330 (3), P30CA014520 (3), P30CA022453 (3), U01CA062491 (3)